Vivimed Labs share news, announcements and annual reports
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.53down ₹0.11 (1.95%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹5.64.
30 Oct: open ₹5.62, high ₹5.64, low ₹5.53
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,267
Vivimed Labs share news and announcements
642 announcements, routine notices left out, newest first. Page 10 of 13.
Aug 2014
5 Aug · Legal
Exchange had sought clarification from Vivimed Labs Limited with respect to a news item captioned "Sebi slaps Rs 10 lakh fine on Vivimed Labs for violation". The Company has clarified that "The company received the order of SEBI on 4th August 2014 for violation of provisions of Clause 20(a) of the Listing Agreement read with Section 21 of the Securities Contracts (Regulation) Act, 1956 (hereinafter referred to as 'SCRA,1956'), Viz., Not intimating the exact date of payment of Dividend/Date of despatch of Dividend warrants (for the financial year 2012-13 ) to the stock Exchanges. SEBI imposed a penalty of Rs.10,00,000/- (Rupees Ten Lakh only) on Vivimed Labs Limited under Section 23E of the SCRA,1956. It has no material impact on its present or future operations or its profitability or its financials".5 Aug · Updates
Trading Window shall, pursuant to the Code of Conduct for prevention of Insider Trading under the SEBI (Prohibition of Insider Trading) Regulations, 1992, remain closed from August 5, 2014 to August 13, 2014 (both days inclusive) and shall reopen after the expiry of 24 hours after the public announcement of un audited financial results is made.1 Aug · Board meeting
Inter alia, to consider and approve the unaudited Financial Results of the Company for the Quarter ended June 30, 2014.
Jul 2014
May 2014
30 May · Dividend
Board of Directors of the Company at their meeting held on May 29, 2014 has recommended a dividend of Rs.3/- (30%) per equity share of Rs.10/- each for the financial year ended March 31, 2014.19 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2014, and recommend dividend, if any, for the financial year 2013-14. In view of this, the Trading Window shall, pursuant to the Code of Conduct for prevention of Insider Trading under the SEBI (Prohibition of Insider Trading) Regulations, 1992, remain closed from May 21, 2014 to May 29, 2014 (both days inclusive) and shall reopen after the expiry of 24 hours after the public announcement of audited financial results is made.14 May · News Verification
News Verification : The media had reports that Vivimed Labs Limited. VIVIMED LABS Likely to Divest Stake in Speciality Chemicals Business. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Vivimed Labs Limited has vide its letter inter-alia stated,"There are no such negotiations were taking place. The company is not aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading."
Apr 2014
Mar 2014
Feb 2014
3 Feb · Board meeting
Inter alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter & Nine Months ended December 31, 2013.
Dec 2013
Nov 2013
5 Nov · Board meeting
Inter alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter & Half year ended September 30, 2013.
Oct 2013
1 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2013
12 Sep · Updates
Vivimed Labs Limited had informed the Exchange that at the meeting of Management Committee of Board of Directors of 'Vivimed Labs Limited' held on September 10, 2013 has allotted 142,857 equity shares of the Company to (1) Dr. Kumar Kurumaddali and (2) Mrs. Prashanthi Alamuru [Swap of shares of FINOSO PHARMA PVT LTD - acquired by VIVIMED LABS LTD]. The Company has now clarify that Management Committee of Board of Directors of the Company held on September 10, 2013 has allotted 142,857 equity shares of the Company at an Issue Price of Rs. 350/- (Face Value Rs. 10/- and Premium Rs. 340/- ) to (1) Dr. Kumar Kurumaddali and (2) Mrs. Prashanthi Alamuru [Pursuant to the resolutions Passed in Extra-Ordinary General Meeting held on March 12, 2013].11 Sep · Business
At the meeting of Management Committee of Board of Directors of 'Vivimed Labs Limited' held on September 10, 2013 has allotted 142,857 equity shares of the Company to (1) Dr. Kumar Kurumaddali and (2) Mrs. Prashanthi Alamuru [Swap of shares of FINOSO PHARMA PVT LTD - acquired by VIVIMED LABS LTD].10 Sep · Meeting
Register of Members and Share Transfer Books shall remain closed from September 26, 2013 to September 30, 2013 (both days inclusive) for the purpose of Annual General Meeting to be held on September 30, 2013 & ascertaining eligibility to dividend.
Aug 2013
5 Aug · Board meeting
Inter alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30, 2013.
Jul 2013
26 Jul · Updates
With reference to the Share Price movement, Vivimed Labs Limited ("Vivimed" or the Company) seeks to issue a clarification regarding the high trading volumes and steep decline in the share price observed over the last three days.In this context, the Company would like to clarify that the fail of its share price is unexpected and unwarranted. The Company would like to assure all shareholders that there is no change in its business fundamentals. Vivimed remains committed to delivering growth and profitability across each of its business segments. The Company believes it is on course to achieving its strategic goals and remains focused on its longer term objective of delivering sustainable value to all stakeholders. The Company would further like to clarify that the 'Promoters' of the Company have informed us that none of the shares pledged by them in their individual capacity have been invoked by their lenders as of date, to warrant this unusual movement."
May 2013
31 May · Dividend
Board of Directors of the Company at their meeting held on May 30, 2013 has recommended a dividend of Rs.3/- (30%) per equity share of Rs.10/- each for the financial year ended March 31, 2013.22 May · Management
Board of Directors, vide a Circular Resolution dated May 15, 2013 has Appointed Dr. V. Peesapati as an Additional Director (Non Executive & Independent) of the Company with effect from May 22, 2013.16 May · Board meeting
To consider the Appointment of Dr. V. Peesapati as an Additional Director (Non Executive & Independent) of the Company.15 May · Board meeting
Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 24,2013 Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013, and recommend dividend, if any, for the financial year 2012-13.. The Company has now informed the Exchange that due to delay in finalization of account and completion of audit, the aforesaid Board Meeting has been postponed and a meeting of the Board of Directors of the Company will be held on May 30, 2013.14 May · Board meeting
Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013, and recommend dividend, if any, for the financial year 2012-13.
Apr 2013
22 Apr · Board meeting
Board of Directors, vide a Circular Resolution dated April 12, 2013 has approved/declared the payment of Pro Rata Dividend on 6,70,000 Compulsorily convertible and Cumulative preference shares (CCPS) (to the then Preference share holder "NYLIM Jacob Ballas India FUND lll,LLC" as per the terms of CCPS) due to its conversion as Equity shares on March 22, 2013.12 Apr · Updates
Resolution by circulation is proposed to be passed by the Board of Directors of the Company on April 20, 2013, to consider Declaration of Pro Rata Dividend on 6,70,000 Compulsorily convertible and Cumulative preference shares (CCPS) (to the then Preference share holder "NYLIM Jacob Ballas India FUND lll,LLC") due to its conversion as Equity shares on March 22, 2013.
Mar 2013